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Abstract
Anti-tumour necrosis factor (TNF)α therapy is highly effective in
rheumatoid arthritis and it is surprising, therefore, that a recent
study showed that intraperitoneal administration of recombinant
TNFα reduced the severity of adjuvant-induced arthritis and
decreased IFNγ expression in cultured draining lymph node cells.
Furthermore, in untreated arthritic rats, maximal TNFα expression in
draining lymph node cells coincided with spontaneous disease
remission, suggesting a role for endogenous TNFα in recovery
from arthritis. If confirmed in further studies, these findings suggest
that, in addition to its well-established pro-inflammatory properties,
TNFα may also play a disease-limiting role in this model of
rheumatoid arthritis by suppressing effector T cell responses.
A recent paper by Kim and colleagues [1] published in this
journal reports that intraperitoneal administration of
recombinant tumour necrosis factor (rTNF)α to rats with
adjuvant-induced arthritis has a beneficial effect on disease
outcome. This is surprising given the efficacy of anti-TNFα
therapy in rheumatoid arthritis (RA) [2], with patients
receiving not only immediate clinical benefit, but also reduced
joint damage in the long-term [3]. How can we reconcile the
fact that blockade of endogenous TNFα is beneficial in
human RA, whereas administration of exogenous rTNFα
reduces disease severity in an animal model of RA?
In response to this question, it is important to bear in mind
that cytokines generally act within their local pericellular
microenvironment. It is conceivable, therefore, that
endogenous TNFα plays a pro-inflammatory role in the joints
of arthritic rats whereas exogenous rTNFα triggers an anti-
inflammatory response when injected into the peritoneal
cavity. For example, injection of rTNFα could induce a
neutralising antibody response against TNFα, or could induce
the production of soluble TNF receptors, which could inhibit
TNFα activity at the site of disease activity. However, the
authors found no evidence of increased levels of anti-TNFα
antibodies or soluble TNF receptor (TNFR) [1].
Another possibility is that administration of TNFα could
induce the production of IL-10, resulting in suppression of
TNFα expression in the joint. Alternatively, injection of rTNFα
could result in activation of the hypothalamic-pituitary-
adrenalin axis, leading to the production of immuno-
suppressive glucocorticoids. Although the authors did not
rule out these possibilities, they did not find any evidence of
generalised immunosuppression in control mice treated with
rTNFα [1]. Another possibility considered by the authors was
the induction of the tryptophan-degrading enzyme indole-
amine 2,3-dioxygenase, which is known to inhibit effector
T cell responses. Again, however, no evidence was found to
support this [1].
It was also shown that the recovery phase of adjuvant-
induced arthritis in Lewis rats coincided with the peak of
TNFα expression in antigen-stimulated draining lymph node
cells, suggesting an immunomodulatory role for endogenous
TNFα in disease remission [1]. In contrast, TNFα expression
was highest in Wistar-Kyoto rats (which are resistant to
adjuvant-induced arthritis) in the immediate post-immuni-
sation period. In the light of these findings, another possibility
to consider is that the pathogenesis of adjuvant-induced
arthritis is fundamentally different to that of RA, such that
TNFα is anti-inflammatory in the former but pro-inflammatory
in the latter. In this respect it is important to point out that in
the study by Kim and colleagues, arthritis was induced by
immunisation with heat-killed Mycobacterium tuberculosis
plus mineral oil [1], both of which may induce arthritis
independently. Hence, multiple arthritogenic factors contri-
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bute to disease induction and it is possible that TNFα plays
different, and perhaps changing, roles in the overall patho-
genesis of this form of arthritis.
In the light of the findings presented by Kim and colleagues
[1], it is interesting that a small number of studies have shown
exacerbation of specific autoimmune diseases by anti-TNFα
therapy. For example, TNFα blockade was shown to increase
both the rate and frequency of relapse in patients with
existing multiple sclerosis [4]. Similarly, in experimental
autoimmune encephalomyelitis (EAE), TNFα-/- mice develop-
ed enhanced inflammation and demyelination, whereas
treatment of susceptible mice with TNFα reduced disease
severity [5]. In another study, EAE failed to resolve in TNFα-/-
or TNFR-/- mice, suggesting that TNFα plays an important role
in resolution of inflammation [6]. In murine lupus it was shown
that administration of rTNFα was protective [7] whereas
TNFα deficiency was associated with increased production
of anti-nuclear antibodies and accelerated onset of disease
[8]. TNFα was also shown to have anti-inflammatory proper-
ties depending on the timing of TNFα expression in a murine
model of autoimmune diabetes [9].
One possibility to consider is that TNFα acts on cells of the
joint (for example, endothelial cells) to promote cellular
infiltration but acts on cells of the adaptive immune system to
suppress T cell responses, possibly as part of a negative
feedback loop. This is supported by the observation by Kim
and colleagues that administration of rTNFα suppressed IFNγ
production by antigen-stimulated T cells. Furthermore,
studies from the laboratory of Cope and colleagues have
shown that prolonged exposure of T cells to TNFα in the
context of RA leads to the induction of hyporesponsiveness
to T cell receptor signalling [10]. However, the fact that Kim
and colleagues did not observe reduced T cell responses in
TNFα treated rats immunised with a control antigen (hen egg
lysozyme) would argue against a generalised immuno-
suppressive effect [1]. Another possibility is that TNFα
modulates antigen presenting cell function, leading to altera-
tions in T cell activity. For example, two recent studies have
shown that TNFα selectively inhibits expression of p40, the
common subunit of IL-12 and IL-23, in human and mouse
myeloid cells, respectively [11,12].
In summary, this paper raises intriguing questions about the
diverse roles played by TNFα in adjuvant-induced arthritis
although further studies will be required to establish their
relevance to human disease.
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